| Acquired by | Sunovion Pharmaceuticals |
| Price | $430M |
| Date | 8/12 |
| Website | elevationpharma.com |
| Category | BioTech |
| Phone | 858-436-1616 |
| info@elevationpha... | |
| Employees | |
| Founded | 2007 |
| Description | biopharmaceutical company |
| TOTAL | $77M |
| VENTURE FUNDING TOTAL | $77M |
| Series A, 1/10 Canaan Partners TPG Growth Care Capital Mesa Verde Venture Partners | $30M |
| Series A, 9/11 Canaan Partners TPG Growth Care Capital Mesa Verde Venture Partners | $17M |
| Series B, 1/12 Novo Ventures Canaan Partners TPG Biotech Care Capital Mesa Verde Venture Partners | $30M |
Founded in 2008, Elevation Pharmaceuticals is developing a pipeline of improved aerosol drug products for COPD patients. There founding team has a successful track record starting companies and building dedicated teams to develop new drug products that improve patients’ lives. At Elevation, they have a disciplined approach to strategic decision-making that helps us stay focused on the path with the highest probability of success. They are executing our drug development plans with passion, integrity, and a high sense of urgency in order to meet the needs and expectations of our stakeholders – employees, investors, partners, and patients.
